The authors suggested that the T cells expressing both receptors will selectively lyse tumour cells because of simultaneous activation with CSPG4 expressed on the tumour and CD20 expressed either on the tumour or on bystander/tumour-infiltrating B cells [95]. The gene discussed is CSPG4; the disease is neoplasm.